pCDH-EF1a-Piranha™-T2A-Puro Pre-packaged Lentivirus

Use ready-to-transduce Piranha lentivirus marked with puro and expressed from the EF1α promoter to build your own targeted protein degradation cell line.

Catalog Number
Add to Cart

pCDH-EF1a-Piranha™-T2A-Puro Lentivirus

>1 x 10^6 IFUs
$ 595
Contact Us Speak to a specialist


Control protein activity quickly and specifically

When you’d like to create your own Piranha™ Targeted Protein Degradation-expressing cell line, SBI’s exclusive, ready-to-transduce pCDH-EF1α-Piranha™-T2A-Puro Pre-pacakged Lentivirus, provides an option for moderate expression in most cell types, including primary cells and stem cells. This construct is marked with puromycin for robust and easy selection of positive transductants. To initiate targeted protein degradation in your Piranha-expressing cell line, simply electroporate in antibody specific for your protein-of-interest—you’ll start seeing degradation of the protein-of-interest in as little as 1 hour*.

While studying protein function in vivo often involves knocking down expression using siRNA or knocking out the gene via CRISPR/Cas9, these approaches are indirect and often imperfect. siRNA can reduce or eliminate protein expression, but if the protein turn-over rate is slow then it can take days to see a reduction in function. Simply knocking out the gene coding for the protein-of-interest is not always possible, limits the type of studies you can do, and is incompatible with essential genes. To give researchers another faster option, SBI developed the Piranha Targeted Protein Degradation System.

  • Specific—avoid off-target effects associated with genomic-based approaches (CRISPR/Cas9) or mRNA targeting (RNAi) by directly targeting the protein-of-interest
  • Fast—observe protein degradation in as little as 1 hour* for speedier, more efficient studies
  • Simple—relies on only two reagents, the Piranha System and your validated antibody
  • Powerful—antibody-based targeting means the Piranha System can selectively degrade the phosphorylated or other post-translationally modified form of a protein while leaving the unmodified form intact
  • Scalable for screening—use either the HEK293T Piranha Cell Line or your own cell line stably expressing Piranha protein to evaluate multiple protein targets in parallel (96- or 384-well plate assays)
  • Unique—the only commercially available system for direct targeted degradation of protein(s)-of-interest for phenotypic studies
  • Flexible—available as electroporation-ready mRNA, constitutively expressed in a HEK293T cell line, or as pre-packaged lentivirus for stable Piranha expression in the cell line of your choice

*Based on published data by Clift et al. A Method for the Acute and Rapid Degradation of Endogenous Proteins. Cell. 2017 Dec 14;171(7):1692-1706.e18. doi: 10.1016/j.cell.2017.10.033.  Degradation rate of target protein and resulting phenotypic effects will depend on the specific protein being targeted and influenced by protein degradation pathway and any compensatory mechanisms.  An initial time course experiment to find optimal conditions to assay for protein knockdown and phenotypes is highly recommended.

Available Piranha Targeted Protein Degradation System Products

Table 1. Available Piranha Targeted Protein Degradation System Products

Cat. #Product
Electroporation-ready mRNA
PTPD500A-1Piranha Electroporation-ready untagged mRNA
PTPD510A-1Piranha Electroporation-ready RFP-tagged mRNA
PTPD520A-1Piranha Electroporation-ready GFP-tagged mRNA
Stable Cell Line
PTPD600A-1Piranha HEK293T GFP/Puromycin Stable Cell Line
Pre-packaged Lentivirus
PTPD513VA-1pCDH-CMV-Piranha-EF1-GFP-T2A-Puro Pre-packaged Lentivirus
PTPD527VA-1pCDH-EF1a-Piranha-T2A-Puro Pre-packaged Lentivirus

How It Works

Targeted Protein Degradation with Piranha

SBI’s Piranha Targeted Protein Degradation System is based on the TRIM21 pathway found in most mammalian cells1 (Figure 1). Like TRIM21, the Piranha protein binds to conserved regions of an antibody, targeting the antibody—and the bound antigen—for degradation by the proteasome.

How the Piranha Targeted Protein Degradation System works

To use your newly-created Piranha-expressing cell line for targeted protein degradation, simply electroporate a validated antibody specific for the protein-of-interest into target cells, wait an appropriate amount of time, and then observe the phenotypic outcome. Because the rate of protein degradation is based upon many factors, we recommend performing initial experiments to empirically determine the degradation rate of your target protein and the optimal time for phenotypic observation.

1. Clift D, et al. A Method for the Acute and Rapid Degradation of Endogenous Proteins. Cell. 2017 Dec 14;171(7):1692-1706.e18. doi: 10.1016/j.cell.2017.10.033.

Supporting Data

See the Piranha Targeted Protein Degradation System in action

Piranha Electroporation-ready mRNA is pure and efficiently delivered and translated inside cells

Figure 2. Piranha Electroporation-ready mRNA is pure and efficiently delivered and translated inside cells. (A) Denaturing RNA gel electrophoresis of Piranha RFP-tagged, untagged, and GFP-tagged mRNA shows clean transcripts of an appropriate size. (B) Fluorescence imaging of HEK293T cells electroporated with Piranha RFP-tagged mRNA shows robust delivery and translation of the construct.

Double Reporter Piranha HEK293T Cells electroporated with anti-IKKα antibody show complete and near-complete ablation of IKKα after one day

Figure 3. Piranha HEK293T Cells electroporated with anti-IKKα antibody show complete and near-complete ablation of IKKα after one day. A validated anti-IKKα antibody was electroporated into Piranha HEK293T cells using two different conditions (A and B), and IKKα protein levels assessed via Western blot and compared to a no-construct control. On day 1 post-electroporation, condition A shows complete ablation of IKKα protein and condition B shows almost complete ablation. By Day 2 levels of IKKα protein begin to return to pre-electroporation levels as the amount of antibody dissipates.

Piranha mRNA and antibody efficiently reduce protein levels at a faster rate than corresponding siRNA

Figure 4. Piranha mRNA and antibody efficiently reduce protein levels at a faster rate than corresponding siRNA. Piranha mRNA and validated anti-IκBα antibody were co-electroporated into HeLa cells (top panel) and IκBα protein levels monitored over time via Western blot. Compared to IκBα levels after introduction of IκBα siRNA (bottom panel), the Piranha System reduces IκBα protein levels faster—reduction is apparent by 8 hours (top panel), whereas for siRNA protein reduction is first apparent only after 24 hours (bottom panel).

The speed of the Piranha System is also evident using a luciferase-based activity assay

Figure 5. The speed of the Piranha System is also evident using a luciferase-based activity assay. MDA-MB-231 breast cancer cells were co-electroporated with Piranha mRNA and anti-IκBα antibody, and IκBα activity measured using an NFκB luciferase reporter assay—lower IκBα levels result in higher NFκB luciferase reporter activity. Compared to reduction of IκBα activity by siRNA (dark gray bars), which peaks on day 2, the Piranha System shows peak reduction of IκBα activity on day 1 (blue bars). The negative control is shown as light gray bars.

The Piranha System can reduce levels of phosphorylated protein

Figure 6. The Piranha System can reduce levels of phosphorylated protein. Piranha HEK293T Cells were electroporated with either buffer only (NC), anti-phospho-AKT(S473) antibody, or an IgG control, and total AKT levels assessed via Western blot.  Within 5-hrs post-electroporation, both phosphorylated and total AKT protein levels are reduced.


  • Winston, C, et al. (2019) Complement protein levels in plasma astrocyte-derived exosomes are abnormal in conversion from mild cognitive impairment to Alzheimer’s disease dementia. Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring. 2019 Dec 1; 11:61-66. Link: Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring
  • Kim, Y & Mok, H. (2019) Citraconylated exosomes for improved internalization into macrophages. Appl Biol Chem. 2019 Dec 1; 62(1). Link: Appl Biol Chem
  • Saunders, CA, et al. (2019) Genetic manipulation of PLB-985 cells and quantification of chemotaxis using the underagarose assay. Methods Cell Biol.. 2019 Oct 29; 149:31-56. PM ID: 30616826
  • Sekiba, K, et al. (2019) Inhibition of HBV Transcription From cccDNA With Nitazoxanide by Targeting the HBx-DDB1 Interaction. Cell Mol Gastroenterol Hepatol. 2019 Oct 24; 7(2):297-312. PM ID: 30704981
  • Yang, JS, et al. (2019) Investigation of lipidomic perturbations in oxidatively stressed subcellular organelles and exosomes by asymmetrical flow field-flow fractionation and nanoflow ultrahigh performance liquid chromatography-tandem mass spectrometry. Anal. Chim. Acta. 2019 Sep 27; 1073:79-89. PM ID: 31146839
  • Ishihara, R, et al. (2019) Design of a surface-functionalized power-free microchip for extracellular vesicle detection utilizing UV grafting. Reactive and Functional Polymers. 2019 Sep 1; 142:183-188. Link: Reactive and Functional Polymers
  • Gamboa, L, et al. (2019) Heat-triggered remote control of CRISPR-dCas9 for tunable transcriptional modulation. bioRxiv. 2019 Aug 14;. Link: bioRxiv
  • Xu, Q, et al. (2019) miR‑132 inhibits high glucose‑induced vascular smooth muscle cell proliferation and migration by targeting E2F5. Mol Med Rep. 2019 Aug 1; 20(2):2012-2020. PM ID: 31257477
  • Liu, L, et al. (2019) IL‑17A promotes CXCR2‑dependent angiogenesis in a mouse model of liver cancer. Mol Med Rep. 2019 Aug 1; 20(2):1065-1074. PM ID: 31173199
  • Hisano, Y, et al. (2019) Lysolipid receptor cross-talk regulates lymphatic endothelial junctions in lymph nodes. J. Exp. Med.. 2019 Jul 1; 216(7):1582-1598. PM ID: 31147448
  • Choi, YW, et al. (2019) Abrogation of B-RafV600E induced senescence by FoxM1 expression. Biochem. Biophys. Res. Commun.. 2019 Jun 30;. PM ID: 31270027
  • Madhu, LN, et al. (2019) Neuroinflammation in Gulf War Illness is linked with HMGB1 and complement activation, which can be discerned from brain-derived extracellular vesicles in the blood. Brain Behav. Immun.. 2019 Jun 27;. PM ID: 31255677
  • Amado, F, et al. (2019) Sample Treatment for Saliva Proteomics. Adv. Exp. Med. Biol.. 2019 Jun 26; 1073:23-56. PM ID: 31236838
  • Tian, L, et al. (2019) Long-read sequencing unveils IGH-DUX4 translocation into the silenced IGH allele in B-cell acute lymphoblastic leukemia. Nat Commun. 2019 Jun 26; 10(1):2789. PM ID: 31243274
  • Chen, CY, et al. (2019) Extracellular vesicles from human urine-derived stem cells prevent osteoporosis by transferring CTHRC1 and OPG. Bone Res. 2019 Jun 26; 7:18. PM ID: 31263627
  • Zhang, L & Li, D. (2019) MORC2 regulates DNA damage response through a PARP1-dependent pathway. Nucleic Acids Research. 2019 Jun 25;. Link: Nucleic Acids Research
  • Ariyoshi, K, et al. (2019) Radiation-Induced Bystander Effect is Mediated by Mitochondrial DNA in Exosome-Like Vesicles. Sci Rep. 2019 Jun 24; 9(1):9103. PM ID: 31235776
  • Lee, H, et al. (2019) Caveolin-1 selectively regulates microRNA sorting into microvesicles after noxious stimuli. J. Exp. Med.. 2019 Jun 24;. PM ID: 31235510
  • Zhao, J, et al. (2019) Tumor-Derived Extracellular Vesicles Inhibit Natural Killer Cell Function in Pancreatic Cancer. Cancers (Basel). 2019 Jun 22; 11(6). PM ID: 31234517
  • Wang, X, et al. (2019) Prostate carcinoma cell-derived exosomal MicroRNA-26a modulates the metastasis and tumor growth of prostate carcinoma. Biomed. Pharmacother.. 2019 Jun 20; 117:109109. PM ID: 31229922